Browse drug registration pathways, regulators, CTD dossier expectations, review procedures, holder duties, and post-approval obligations by country.
Public pages show drug registration overviews; during the limited-time free period, sign in or register to view complete pathways.
Drug registration routes in the same region often share CTD structure, local holder, GMP/CPP, label-language, and post-approval patterns. Start with the regional pattern, then open the country page for differences.
Typical flow: local holder or agent, CTD/eCTD, CPP/GMP, label-language work, and pharmacovigilance setup. LATAM markets often require Spanish/Portuguese localization and may focus on BE or clinical bridging.
Typical flow: local MAH/agent, CTD or ASEAN CTD, GMP/CPP, samples/testing, and label-language checks. ASEAN markets share dossier logic; China, Japan, and Korea have heavier local clinical and administrative requirements.
Typical flow: EU CTD, centralized/MRP/DCP/national route, QP/PV system, SmPC/PIL, and local languages. UK, Switzerland, and other non-EU markets require separate holders and filing routes.
Typical flow: local agent or holder, CTD, CPP/GMP, legalization, Arabic labeling, and local pharmacovigilance contact. GCC markets can reference one another but still keep local submission and fee steps.
7 countries
Typical flow: local holder or agent, CTD/eCTD, CPP/GMP, label-language work, and pharmacovigilance setup. LATAM markets often require Spanish/Portuguese localization and may focus on BE or clinical bridging.
Market Overview Market profile: Argentina is shaped by public procurement, private insurance, price controls, and FX constraints. Local pharmaceutical capability is strong, while i...
Updated: 2026-05-04
Market Overview Market profile: Brazil is Latin America's largest pharmaceutical market. SUS procurement, private channels, local manufacturing preference, and Portuguese complianc...
Updated: 2026-05-04
Market Overview Market profile: Canada has high regulatory quality expectations. English/French labeling, NDS/ANDS pathways, patent linkage, and provincial reimbursement are critic...
Updated: 2026-05-04
Market Overview Market profile: Chile has a relatively transparent regulatory environment and high import dependence. ISP registration is required before import, distribution, and...
Updated: 2026-05-04
Market Overview Market profile: INVIMA regulates medicines and biologics. Public insurance, EPS entities, and hospital procurement shape commercial access. Regulatory maturity: Med...
Updated: 2026-05-04
Market Overview Market profile: Mexico is a core Latin American pharmaceutical market. COFEPRIS registration, public procurement, private pharmacy channels, and Spanish labeling ar...
Updated: 2026-05-04
Market Overview Market profile: The United States is the largest global prescription drug and biologics market. Commercial upside is high, but evidence expectations, clinical devel...
Updated: 2026-05-04
12 countries
Typical flow: local MAH/agent, CTD or ASEAN CTD, GMP/CPP, samples/testing, and label-language checks. ASEAN markets share dossier logic; China, Japan, and Korea have heavier local clinical and administrative requirements.
Market Overview Market profile: Australia has a transparent regulatory system. TGA registration and PBS reimbursement are separate but connected market access steps. Regulatory mat...
Updated: 2026-05-04
Market Overview Market profile: Drug registration in China is led by NMPA, with CDE conducting core technical review. Innovative drugs, modified new drugs, generics, biologics, and...
Updated: 2026-05-04
Market Overview Market profile: India is a global hub for generics and APIs and a fastgrowing domestic medicine market. Price control, clinical trials, import licensing, and local...
Updated: 2026-05-04
Public Summary Who this is for: Foreign pharmaceutical manufacturers, registration applicants, importers, and commercial teams planning Indonesia market entry. Regulator: Badan Pen...
Updated: 2026-05-04
Market Overview Market profile: Japan is a highvalue pharmaceutical market. PMDA review quality, NHI pricing, Japanese dossier materials, and local MAH structure are critical. Regu...
Updated: 2026-05-04
Public Summary Who this is for: Foreign holders and local applicants preparing to register new drugs, generics, biologics, health supplements, or natural products in Malaysia. Regu...
Updated: 2026-05-04
Market Overview Market profile: The Philippines pharmaceutical market is driven by generics, prescription medicines, hospitals, and pharmacy channels. Product registration, LTO, an...
Updated: 2026-05-04
Market Overview Market profile: Singapore is a smaller market by volume, but it is highly transparent, Englishfriendly, and important for innovative drugs, generics, biosimilars, a...
Updated: 2026-05-04
Market Overview Market profile: South Korea has a mature pharmaceutical regulatory system with defined pathways for innovative drugs, biosimilars, and generics. Korean materials an...
Updated: 2026-05-04
Market Overview Market profile: Taiwan has a mature drug registration system. TFDA approval and National Health Insurance reimbursement are connected but separate access steps. Reg...
Updated: 2026-05-04
Public Summary Who this is for: Foreign companies planning to register, import, or launch new drugs, generics, biologics, vaccines, or specialcategory medicines in Thailand. Regula...
Updated: 2026-05-04
Market Overview Market profile: Vietnam's pharmaceutical market is growing quickly. Hospital procurement, imported drugs, generics, local manufacturing, and reimbursement all shape...
Updated: 2026-05-04
6 countries
Typical flow: EU CTD, centralized/MRP/DCP/national route, QP/PV system, SmPC/PIL, and local languages. UK, Switzerland, and other non-EU markets require separate holders and filing routes.
Market Overview Market profile: EU pharmaceutical regulation combines EMA, the European Commission, and national competent authorities. A centralised authorisation can cover EU Mem...
Updated: 2026-05-04
Market Overview Market profile: Russia and EAEU medicine registration involves the interface between national pathways and EAEU unified rules. Geopolitical, sanctions, payment, and...
Updated: 2026-05-04
Market Overview Market profile: Switzerland is a highvalue medicine market with rigorous Swissmedic review. Marketing authorisation and BAG/reimbursement pricing are separate steps...
Updated: 2026-05-04
Market Overview Market profile: Turkey is shaped by localisation policy, external reference pricing, reimbursement, and import controls. Local MAH structure is critical. Regulatory...
Updated: 2026-05-04
Market Overview Market profile: Ukraine pharmaceutical registration is affected by war, supply chain, import, payment, and regulator capacity factors. Safety and compliance risk mu...
Updated: 2026-05-04
Market Overview Market profile: After Brexit, medicines are authorised by MHRA, while NHS, NICE, pricing, and reimbursement determine commercial access. Regulatory maturity: High....
Updated: 2026-05-04
8 countries
Typical flow: local agent or holder, CTD, CPP/GMP, legalization, Arabic labeling, and local pharmacovigilance contact. GCC markets can reference one another but still keep local submission and fee steps.
Market Overview Market profile: Egypt is a major pharmaceutical market in Africa and the Middle East. Public procurement, local manufacturing, import controls, and Arabic labeling...
Updated: 2026-05-04
Market Overview Market profile: Israel is a technically mature pharmaceutical market. MOH registration, Hebrew materials, pharmacovigilance, and health basket access are critical....
Updated: 2026-05-04
Market Overview Market profile: Kenya is an East African pharmaceutical hub. Public procurement, importer networks, and quality oversight strongly affect entry. Regulatory maturity...
Updated: 2026-05-04
Market Overview Market profile: Kuwait is dominated by the public healthcare system and import channels. GCC and referencemarket approvals from SFDA/EMA/FDA often have practical va...
Updated: 2026-05-04
Market Overview Market profile: Nigeria has a large population, high import dependence, and major risks from counterfeit/substandard medicines and FX availability. Regulatory matur...
Updated: 2026-05-04
Market Overview Market profile: Saudi Arabia is one of the largest pharmaceutical markets in the GCC. Government procurement, public hospitals, and localisation policy strongly sha...
Updated: 2026-05-04
Market Overview Market profile: South Africa is one of the most mature pharmaceutical markets in subSaharan Africa. SAHPRA registration and public/private procurement jointly shape...
Updated: 2026-05-04
Market Overview Market profile: The UAE is a GCC and Middle East commercial hub. MOHAP federal registration, emirate healthcare systems, importers, and pharmacy channels jointly sh...
Updated: 2026-05-04
